Favorable Safety and Pharmacokinetic Profile, and Broad Therapeutic Window
Non-human primate (NHP) toxicology study validates the CAPTN-3 masking strategy, with IM1240 showing an 8-fold longer half-life, 16-fold greater exposure, and a markedly improved cytokine-release safety profile compared to the non-capped variant
IM1240 demonstrated anti-tumor activity across PD-1- and chemotherapy-resistant patient-derived tumor samples in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a key contributor to this anti-tumor efficacy
IM1240 induced immune cell structures associated with effective anti-tumor responses and a favorable prognosis in patient-derived non-small cell lung cancer (NSCLC) explants
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.